References
- Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-43. https://doi.org/10.1016/S0002-9610(03)00066-7
- Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34. https://doi.org/10.1016/S1470-2045(07)70039-6
- Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. https://doi.org/10.1056/NEJMoa1112088
- Bekkar S, Gronnier C, Messager M, et al. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma. Ann Thorac Surg 2014;97:303-10. https://doi.org/10.1016/j.athoracsur.2013.09.010
- Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337:161-7. https://doi.org/10.1056/NEJM199707173370304
- Hong JC, Murphy JD, Wang SJ, Koong AC, Chang DT. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis. Ann Surg Oncol 2013;20:3999-4007. https://doi.org/10.1245/s10434-013-3072-9
- Knox JJ, Wong R, Visbal AL, et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer 2010;116:4023-32. https://doi.org/10.1002/cncr.25349
- Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol 2014;32:385-91.
- Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92. https://doi.org/10.1016/S1470-2045(11)70142-5
- Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26: 1086-92. https://doi.org/10.1200/JCO.2007.12.9593
- Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7. https://doi.org/10.1056/NEJM199608153350702
- Hamai Y, Hihara J, Taomoto J, Yamakita I, Ibuki Y, Okada M. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer. Dis Esophagus 2015;28:358-64. https://doi.org/10.1111/dote.12207
- Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg 2014;101:321-38. https://doi.org/10.1002/bjs.9418
- Lin FC, Durkin AE, Ferguson MK. Induction therapy does not increase surgical morbidity after esophagectomy for cancer. Ann Thorac Surg 2004;78:1783-9. https://doi.org/10.1016/j.athoracsur.2004.04.081
- Merritt RE, Whyte RI, D'Arcy NT, Hoang CD, Shrager JB. Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. Ann Thorac Surg 2011;92: 2034-40. https://doi.org/10.1016/j.athoracsur.2011.05.121
- Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13. https://doi.org/10.1200/JCO.2001.19.2.305
- Delanian S, Lefaix JL. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol 2007;17:99-107. https://doi.org/10.1016/j.semradonc.2006.11.006
- Iannettoni MD, Whyte RI, Orringer MB. Catastrophic complications of the cervical esophagogastric anastomosis. J Thorac Cardiovasc Surg 1995;110:1493-500. https://doi.org/10.1016/S0022-5223(95)70072-2
- Gronnier C, Trechot B, Duhamel A, et al. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study. Ann Surg 2014;260:764-70. https://doi.org/10.1097/SLA.0000000000000955
- Kim JY, Correa AM, Vaporciyan AA, et al. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 2012;93:207-12. https://doi.org/10.1016/j.athoracsur.2011.05.021
- Ruol A, Rizzetto C, Castoro C, et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? Ann Surg 2010;252: 788-96. https://doi.org/10.1097/SLA.0b013e3181fc7f86
- Tessier W, Gronnier C, Messager M, et al. Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer? Ann Thorac Surg 2014;97:1181-9. https://doi.org/10.1016/j.athoracsur.2013.12.026
- Shaikh T, Ruth K, Scott WJ, et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg 2015;99:270-6. https://doi.org/10.1016/j.athoracsur.2014.08.033
- Franko J, Voynov G, Goldman CD. Esophagectomy timing after neoadjuvant therapy for distal esophageal adenocarcinoma. Ann Thorac Surg 2016;101:1123-30. https://doi.org/10.1016/j.athoracsur.2015.09.044
- Lee A, Wong AT, Schwartz D, Weiner JP, Osborn VW, Schreiber D. Is there a benefit to prolonging the interval between neoadjuvant chemoradiation and esophagectomy in esophageal cancer? Ann Thorac Surg 2016;102:433-8. https://doi.org/10.1016/j.athoracsur.2016.02.058
- Liedman B, Johnsson E, Merke C, Ruth M, Lundell L. Preoperative adjuvant radiochemotherapy may increase the risk in patients undergoing thoracoabdominal esophageal resections. Dig Surg 2001;18:169-75. https://doi.org/10.1159/000050125
- Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-7. https://doi.org/10.1200/JCO.2005.05.017
- Dewar L, Gelfand G, Finley RJ, Evans K, Inculet R, Nelems B. Factors affecting cervical anastomotic leak and stricture formation following esophagogastrectomy and gastric tube interposition. Am J Surg 1992;163:484-9. https://doi.org/10.1016/0002-9610(92)90393-6
Cited by
- Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia vol.17, pp.1, 2019, https://doi.org/10.1186/s12957-019-1712-7
- Constructing a risk prediction model for anastomotic leakage after esophageal cancer resection vol.48, pp.4, 2019, https://doi.org/10.1177/0300060519896726
- Fluorescence Image-Based Evaluation of Gastric Tube Perfusion during Esophagogastrostomy vol.53, pp.4, 2020, https://doi.org/10.5090/kjtcs.2020.53.4.178
- Specific complications and limitations of robotic esophagectomy vol.33, pp.suppl2, 2019, https://doi.org/10.1093/dote/doaa109
- Predictors of Anastomotic Leak After Esophagectomy for Cancer: Not All Leaks Increase Mortality vol.87, pp.6, 2021, https://doi.org/10.1177/0003134820956329
- Anastomotic leakage and postoperative mortality in patients after esophageal cancer resection vol.49, pp.9, 2021, https://doi.org/10.1177/03000605211045540